View clinical trials related to Wilson Disease.
Filter by:Primary objective - Collection of patients with wilson disease either presented with neurological or hepatic symptoms - Assessment of psychiatric and cognitive disorders in both groups by using specific scales Secondary objective - correlation of MRI brain findings with cognitive & psychiatric symptoms found in the patients ,if possible.
The assumption is that in some of the carriers, the increase in enzymes reflects tissue damage due to excess copper. The reduction of the amount of copper absorbed will decrease excess copper in the liver, which will result in a decrease in the level of liver enzymes. Zinc causes the induction of metalothionines in the intestine, which in turn prevents absorption of copper from the digestive system. Zinc administration in Wilson's patients causes the depletion of copper deposits and constitutes one of the cornerstones in the treatment of this disease.